Phase 1 N=21 Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
Carcinoma, Basal Cell (BCC)
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 1; 12 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=331 OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Diabetes Mellitus, Type 2
Primary: Between Group Difference in HbA1c When Comparing CSII to MDI — -1.1; -0.4 Change in % HbA1c
Phase 4 N=76 The Effectiveness of Lubiprostone in Constipated Diabetics
Constipation · Diabetes
Primary: Efficacy, Measured by the Average Number of Spontaneous Bowel Movements (SBMs) Per Week — 4.85; 1.40; 3.81; 2.41 spontaneous bowel movements
Phase 4 N=61 Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)
Short Stature Born Small for Gestational Age (SGA)
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 27; 31; 10; 5 participant
Phase 3 N=850 Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
Heart Transplantation · Liver Transplantation · Kidney Transplantation
Primary: Participant Survival — 0.9092; 1.0000; 0.9356; 0.9031 survival probability
N/A N=459 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
Migraine Disorders · Headache
Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants
Phase 2 N=63 Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Malignant Neoplasm
Primary: Cmax Following Single Dose of Drug — 3244; 5666; 3511 ng/ml — p=0.003
Phase 2 N=30 Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Progression-free Survival — 29 months
Phase 4 N=276 Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
End Stage Renal Disease
Primary: EPO Dose — 5800; 5400; 7000; 6050 units/week — p=0.78
Phase 4 N=86 Reducing Pain of Lidocaine Injection
Pain of Anesthesia at Breast Biopsy
Primary: Pain — 1.19; 0.56 units on a scale
Phase 4 N=139 Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication
Elective Orthopedic Surgery
Primary: Scores on the Verbal Rating Scale For Anxiety — 1.8; 2.3; 2.8 Scores on a Scale (0-10)
Phase 2 N=48 Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Stomach Neoplasms · Esophageal Neoplasms
Primary: 6 Month Progression Free Survival — 79 percentage of participants
Phase 3 N=461 Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
Lupus Erythematosus, Systemic
Primary: Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B — 57.32; 36.11; 53.25 percentage of…
N/A N=94 Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy
Chronic Pain
Primary: Brief Pain Inventory (BPI): Number of Participants With a Pain Reduction of Greater Than or Equal to 30% — 17; 5 participants — p=0.0048
N/A N=70 Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery
Pain
Primary: Quality of Recovery at 24 Hours(QoR-40 Instrument) — 189; 183 units on a scale — p=.01